Global Graft Versus Host Disease (GvHD) Pipeline Landscape, H1 2020: Therapeutics, Developments, Products, Drugs, Players -

DUBLIN--()--The "Graft Versus Host Disease (GvHD) - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This pipeline guide provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

The guide provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GvHD) and features dormant and discontinued projects.

Furthermore, it covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 39, 11, 3, 43, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Key Topics Covered

  1. Introduction
  2. Overview
  3. Therapeutics Development
  4. Therapeutics Assessment
  5. Companies Involved in Therapeutics Development
  6. Drug Profiles
  7. Dormant Projects
  8. Discontinued Products
  9. Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • AbGenomics International Inc
  • Adienne Pharma & Biotech
  • Alpine Immune Sciences Inc
  • Amgen Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • ASC Therapeutics Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Autolus Therapeutics Plc
  • Bellicum Pharmaceuticals Inc
  • Biocon Ltd
  • Biogen Inc
  • BioIncept LLC
  • BlueRock Therapeutics
  • Boryung ViGenCell Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cellix Bio Pvt Ltd
  • CheckPoint Immunology Inc
  • Clinigen Group Plc
  • CSL Ltd
  • CTI BioPharma Corp
  • Cytodyn Inc
  • Cytopeutics Pte Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dualogics Corp
  • Eli Lilly and Co
  • Elsalys Biotech SA
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Fujifilm Holdings Corp
  • Generon (Shanghai) Corp Ltd
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Glia LLC
  • Humanigen Inc
  • Immplacate
  • Immune Modulation Inc
  • ImmuneTarget Inc
  • Imstem Biotechnology Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • JN Biosciences LLC
  • Kadmon Corp LLC
  • Kalytera Therapeutics Inc
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kiniksa Pharmaceuticals Ltd
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • Machavert Pharmaceuticals LLC
  • Magenta Therapeutics Inc
  • Mallinckrodt Plc
  • Medac Pharma Inc
  • Medicenna Therapeutics Corp
  • Medsenic SAS
  • Mereo Biopharma Group Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • NapaJen Pharma Inc
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Ocugen Inc
  • OncoImmune Inc
  • OSE Immunotherapeutics
  • Panorama Research Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • Precision Biosciences Inc
  • REGiMMUNE Corp
  • Sanofi
  • SCM lifescience Co Ltd
  • Seattle Genetics Inc
  • Secura Bio Inc
  • STERO Biotechs Ltd
  • Suzhou Connect Biopharmaceuticals Ltd
  • Syndax Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Taiwan Bio Therapeutics Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TCF GmbH
  • TeraImmune Inc
  • TGV Laboratories Inc
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Visterra Inc
  • Xenikos BV
  • Xenothera SAS
  • XL-protein GmbH

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900